PRESS RELEASE 2013

• Ferring Pharmaceuticals appoints Alex Chang Senior Vice President, Asia Pacific

By pulse in PRESS RELEASE 2013 on 01 November 2013
Ferring Pharmaceuticals announced today that it has appointed Alex Chang to head the company’s Asia Pacific region effective 1 November 2013…

• MISODEL™, Ferring’s removable misoprostol vaginal delivery system, approved for labour induction in European Decentralised Procedure

By pulse in PRESS RELEASE 2013 on 17 October 2013
Ferring Pharmaceuticals announced today that its MISODELTM (misoprostol) removable, controlled-release vaginal delivery system for labour induction…

• Ferring announces second $3 million donation to the Royal Textile Academy of Bhutan

By pulse in PRESS RELEASE 2013 on 05 June 2013
Ferring Pharmaceuticals has announced a second $3 million donation to the Royal Textile Academy of Bhutan to support its mission to preserve and…

• Ferring presents phase III data for a controlled release misoprostol vaginal delivery system for labour induction at the First European Congress on Intrapartum Care

By pulse in PRESS RELEASE 2013 on 24 May 2013
Data from the EXPEDITE study presented today at the First European Congress on Intrapartum Care (ECIC) demonstrated…

• Ferring Pharmaceuticals begins phase III trials of elobixibat, new compound with novel mechanism of action for chronic idiopathic constipation

By pulse in PRESS RELEASE 2013 on 02 May 2013
Ferring Pharmaceuticals today announced it has initiated enrolment of patients in two phase III clinical trials…

• Ferring to Present Safety Analysis for FIRMAGON® (degarelix) at the American Urological Association Annual Meeting

By pulse in PRESS RELEASE 2013 on 01 May 2013
The following data will be presented at the annual meeting of the American Urological Association (AUA) in San Diego…

• New data highlight considerable burden of Nocturia

By pulse in PRESS RELEASE 2013 on 17 March 2013
New data presented today at the European Association of Urology (EAU) congress show that nocturia (waking up one or more times to void at night)…

• Data suggest lower risk of cardiovascular events or deaths in prostate cancer patients treated with degarelix compared to LHRH agonists

By pulse in PRESS RELEASE 2013 on 17 March 2013
Data presented today at the European Association of Urology (EAU) 2013 annual meeting in Milan, indicate that the gonadotropin releasing hormone…

• In patients with active, left-sided ulcerative colitis, study shows once-daily dose of mesalazine granules provided similar results to twice-daily dose

By pulse in PRESS RELEASE 2013 on 14 February 2013
Results of a recent sub analysis1 of data from the MOTUS study2 presented today at the Congress of European Crohn’s and Colitis Organisation…